Microba Life Sciences

What Microba Life Sciences does

Microba Life Sciences (ASX: MAP) is a Brisbane-based precision microbiome diagnostics company that commercialises clinical-grade gut microbiome testing through a three-tiered product family — Microbiome Explorer Essentials, Extended, and Comprehensive — sold primarily via a practitioner-referral model to nutritionists, naturopaths, dietitians, integrative GPs, and functional medicine practitioners across Australia and the United Kingdom. The company combines metagenomic next-generation sequencing (mNGS), ELISA, and RT-PCR in a single integrated report, anchored by its proprietary Gut Microbiome Reference Catalogue (GMRC) covering 100% of known human gut microbiome species and a library of 75+ evidence-graded personalised insights grounded in 1,500+ peer-reviewed studies.

The underlying technology stack is run from a NATA-accredited (ISO 15189, plus ISO 13485 for bioinformatics) laboratory in Brisbane that produces interactive digital reports for both practitioners and patients; UK customer relationships and GDPR data-controller responsibilities are handled through the wholly-owned subsidiary Invivo Clinical Ltd (trading as Invivo Healthcare). Distribution is hybrid: direct sales through the practitioner portal and a 27-account enterprise channel in Australia, channel partnerships with Genova, Psomagen and Luminary for US test delivery, and a strategic global distribution alliance with Sonic Healthcare, which also holds approximately 20% equity following its November 2022 A$17.8M investment and an A$8.3M follow-on capacity commitment used to back the June 2026 capital raise.

Microba monetises on a per-test, one-time-license basis with optional practitioner- or patient-pay routing, supplemented by fees for expert interpretation consults. Q3 FY26 revenue of A$3.36M (up 62% year-over-year) and a 23,000+ annualized test run rate place the company in active scale-up mode, with management guiding to over 24,000 core tests for the full financial year and a targeted path to cashflow breakeven by end of CY2027 funded in part by a A$5M placement plus A$1M shareholder purchase plan completed in June 2026.

Name

Microba Life Sciences

Legal name

Microba Pty Limited

Website

https://microba.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

Microba Life Sciences (ASX: MAP) is a Brisbane-based precision microbiome diagnostics company that sells clinical-grade gut microbiome testing (Microbiome Explorer Essentials, Extended and Comprehensive) to healthcare practitioners and their patients in Australia and the UK, using proprietary metagenomic sequencing and a 100%-coverage reference catalogue.

Ownership category

akta.pro rank

Product category

Clinical Microbiome Diagnostics

NAICS

Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro industry

PRIMARYHLAAAFAH

Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)

Healthcare & Life Sciences/Biotechnology & Biologics/Microbiome Therapeutics

SECONDARYHLAGANAH

Microbiome & Metagenomics Services

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

SECONDARYHLAFAMAD

Microbiology & Infectious Disease Testing Laboratories

Healthcare & Life Sciences/Healthcare Providers & Systems/Clinical Laboratories

SECONDARYHLAAAFAI

Microbiome Analytics, Sequencing & Bioinformatics Platforms

Healthcare & Life Sciences/Biotechnology & Biologics/Microbiome Therapeutics

Keywords

• Microbiome testing services
• Clinical gut diagnostics
• Metagenomic sequencing analysis
• GI health biomarkers
• Precision microbiome science

Headquarters

HQ city

Brisbane

HQ country

Australia

HQ region

Oceania

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Microbiome Testing Services: Revenue generated from clinical-grade microbiome testing services sold to healthcare practitioners who refer tests for their patients. Tests are ordered through a practitioner portal and results delivered via interactive digital reports with interpretation support.
2. Clinical Support Services: Revenue includes fees for interpretation support, expert one-on-one case consults with microbiome specialists, and onboarding support services for practitioners.

Go-to-market motion4 records

Distribution channels5 records

Marketing channels7 records

Core offering

Microba delivers clinical-grade gut microbiome testing through the Microbiome Explorer product range (Essentials, Extended, Comprehensive), combining metagenomic next-generation sequencing, ELISA-based GI health markers, and RT-PCR pathogen screening in a single report. Tests are ordered by healthcare practitioners via a web portal and produce evidence-graded personalized insights on diet, lifestyle, and supplements backed by 1,500+ peer-reviewed studies. Samples are processed in an ISO 15189-accredited laboratory in Brisbane, Australia.

Product overview

Microba offers the Microbiome Explorer range, a three-tiered clinical-grade microbiome testing platform consisting of Essentials, Extended, and Comprehensive variants. The range combines multiple testing technologies (metagenomic next-generation sequencing, ELISA, and RT-PCR) in a single unified report. Essentials provides core microbiome profiling with 16 markers and 60+ insights; Extended adds 7 GI health markers for a total of 23 biomarkers with 75+ insights; Comprehensive is the full-featured offering combining all three technology panels with 40 biomarkers, 18 pathogen markers, and 75+ insights. All tests are supported by the Microba ClearCare Insights system, backed by 1,500+ peer-reviewed studies, and delivered through a practitioner portal with shareable digital reports.

Differentiator

Problem solved

Functional benefit

Brands

• Microbiome Explorer: Clinical-grade microbiome testing product range including Essentials, Extended, and Comprehensive tests using metagenomic next-generation sequencing technology.

Products and services

• Microbiome Explorer Essentials The essential-tier gut microbiome test using metagenomic next-generation sequencing, delivering 16 microbiome markers and 60+ evidence-graded personalized insights on diet, lifestyle, and supplements for patients' systemic health.
• Microbiome Explorer Extended The extended-tier test combining 16 metagenomic microbiome markers with 7 diagnostic GI health markers via ELISA technology, delivering 23 total biomarkers and 75+ evidence-graded insights for practitioners managing patients with gut and systemic health concerns.
• Microbiome Explorer Comprehensive The comprehensive gut microbiome test combining metagenomic next-generation sequencing (mNGS), ELISA-based GI health markers, and RT-PCR pathogen screening in one report, delivering 40 functional biomarkers, 18 pathogen markers, and 75+ evidence-graded personalized insights on diet, lifestyle, and supplements.

Quantifiable outcome

• 99% year-over-year revenue growth in Q3 FY26
• +4 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core, regional and minor.

• Invivo Clinical Ltd (Invivo Healthcare)coreChannel Partner/ Reseller/ DistributorInvivo Clinical Ltd manages UK customer relationships and distribution of microbiome testing services. Invivo is now part of Microba, combining Invivo's clinical practice and market presence with Microba's microbiome science and technology. Data controller for UK customers under UK GDPR.
• GenovaregionalChannel Partner/ Reseller/ DistributorGenova is Microba's US partner for test delivery, having launched Microbiomix - a legacy insight product. Collaboration enables US market access for Microba's testing technology.
• PsomagenminorChannel Partner/ Reseller/ DistributorMicroba has worked with Psomagen on US market implementation, similar to the Genova partnership arrangement.
• LuminaryminorChannel Partner/ Reseller/ DistributorMicroba has worked with Luminary on similar implementations for US market access.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Clinical Microbiomics (acquired by OraSure Technologies): Microbiome sequencing and bioinformatics services provider with deep expertise in shotgun metagenomics for clinical and research customers. Comparable to Microba in offering metagenomics-based microbiome analysis at clinical-grade quality for healthcare and research customers.
• ZOE: UK-based personalized nutrition company combining gut microbiome testing with continuous glucose monitoring and dietary analysis. Comparable to Microba as a UK-headquartered microbiome testing competitor addressing similar practitioner and consumer gut-health segments.
• DayTwo: Microbiome-based personalized nutrition company that translates gut microbiome profiles into food and glycemic recommendations. Comparable to Microba in combining clinical-grade microbiome testing with actionable dietary insights for chronic conditions (notably metabolic health).
• Viome: US-based direct-to-consumer and practitioner-focused gut microbiome testing company using metagenomic sequencing to deliver personalized nutrition insights. Comparable to Microba in core technology (mNGS-based gut microbiome profiling) and target end-users seeking personalized microbiome-driven recommendations.
• Genetic Analysis AS: Norwegian diagnostics company with the GA-map platform for gut microbiome dysbiosis testing, sold to clinicians and labs. Comparable to Microba as a clinical-grade microbiome diagnostics platform targeting similar clinical practitioner customers with dysbiosis-focused testing.
• Atlas Biomed: UK- and Russia-based microbiome and DNA testing company offering gut microbiome analysis with personalized health recommendations. Comparable to Microba in the European practitioner/consumer microbiome testing market and in using sequencing-based gut profiling.
• CosmosID: US-based microbial genomics company providing microbiome sequencing and bioinformatics services to researchers, food/feed companies, and clinical applications. Comparable to Microba in the underlying metagenomics and microbiome analytics technology stack, though oriented toward research/B2B rather than practitioner-referral testing.
• Map My Gut: UK-based practitioner-focused gut microbiome testing service combining DNA sequencing with practitioner-led interpretation. Comparable to Microba in serving the UK practitioner market with clinical microbiome testing and personalized recommendations.
• Thryve (now part of Sodexo/Care Innovation): Microbiome testing and insights platform that translates gut microbiome data into personalized health recommendations. Comparable to Microba in the gut microbiome testing category and in serving B2B health/wellness customers with personalized microbiome insights.

Broad incumbents

• Sonic Healthcare: Global medical diagnostics and laboratory services company that is both Microba's largest shareholder (~20%) and primary international distribution partner. Comparable as the incumbent clinical laboratory network through which Microba's tests reach global markets — though Sonic's portfolio is far broader than microbiome testing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/MicrobaOfficial
• LinkedInlinkedin.com/company/microba
• Instagraminstagram.com/mymicroba
• Xx.com/MicrobaOfficial

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Microba Life Sciences